Watchful waiting and active surveillance approach in patients with low risk localized prostatic cancer: An experience of out-patients clinic with 12-year follow-up

Pathology and Oncology Research

Volumn 17, Issue 4, 2011, Pages 893-897

  Kravchick, Sergey ^a   Peled, Ronit ^b   Cytron, Shmuel ^a  

^a BARZILAI MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Body mass index; Cancer; Expectant management; Prostate; TRUS biopsy

Indexed keywords

AGED; ARTICLE; BODY MASS; CANCER LOCALIZATION; CANCER RISK; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PROSTATE BIOPSY; PROSTATE CANCER; WATCHFUL WAITING;

AGED; BIOPSY; BODY MASS INDEX; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTPATIENTS; PROSTATIC NEOPLASMS; RISK; WATCHFUL WAITING;

EID: 84855431344     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9400-0     Document Type: Article

References (19)

1. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
2. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368-374 (Pubitemid 24037911)
3. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI (2007) Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178(6):2359-2364, discussion 2364-5
4. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR (2008) What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 180(4):1330-1334
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (5):373-383 (Pubitemid 17055592)
6. Nash PH, Bruce JE, Indudhara R, Shinohara K (1996) Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 155:607-609 (Pubitemid 26023554)
7. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 54(6):1306-1313
8. Bastian PJ, Mangold LA, Epstein JI, Partin AW(2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101(9):2001-2005 (Pubitemid 39425375)
9. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA (2010) The Epstein criteria predict for organconfined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 58(1):90-95, Epub 2009 Oct 23
10. Klotz L (2004) Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 172(5 Pt 2):S48-S50, discussion S50-1
11. Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH (2006) Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50(3):475-482, Epub 2006 May 3 (Pubitemid 44189069)
12. Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S (2008) Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286-292
13. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12):868-878 (Pubitemid 36833878)
14. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH (2007) Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 177(1):107-112, discussion 112 (Pubitemid 44879468)
15. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17):2095-2101 (Pubitemid 40617061)
16. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR (2008) Active surveillance for earlystage prostate cancer: Review of the current literature. Cancer 112 (8):1650-1659 (Pubitemid 351536825)
17. Stav K, Leibovici D, Sandbank J, Lindner A, Zisman A (2008) Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 71(3):399-403 (Pubitemid 351374732)
18. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C (2001) Marberger M Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: Results of a prospective European prostate cancer detection study. J Urol 166(3):856-860 (Pubitemid 32750966)
19. Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW (1999) Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 84(6):652-656 (Pubitemid 29457182)